In 2025, the biotechnology industry stands at one of the most consequential inflection points in its history. For the past decade, modalities such as mRNA therapeutics, engineered cell therapies, and CRISPR-based gene editing have transitioned from bold scientific experiments to clinical realities with real patients, real outcomes, and billion-dollar markets. The pipeline is richer than […]